Previous close | 92.70 |
Open | 94.25 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 94.25 - 94.25 |
52-week range | 86.12 - 114.90 |
Volume | |
Avg. volume | 42,812 |
Market cap | 117.646B |
Beta (5Y monthly) | 0.45 |
PE ratio (TTM) | 20.53 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.06 (4.38%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.
In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]